Advertisement
Screener

Alkermes plc. (ALKS) Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations

2.3 / 5 stars · 41/89 Roast Me

Alkermes plc. Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations

Alkermes plc. (ALKS) reported Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations of -$700.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-25.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems · last filed 2026-02-25

  • Alkermes plc. income tax expense (benefit), continuing operations, discontinued operations for fiscal 2024 was -$700.00K.
  • Alkermes plc. income tax expense (benefit), continuing operations, discontinued operations for fiscal 2023 was -$1.40M.
  • Alkermes plc. income tax expense (benefit), continuing operations, discontinued operations for fiscal 2022 was -$11.10M.
  • Alkermes plc. income tax expense (benefit), continuing operations, discontinued operations for fiscal 2021 was -$2.50M.
Period endIncome Tax Expense (Benefit), Continuing Operations, Discontinued Operations 12 month
2024-12-31-$700.00K
10-K · filed 2026-02-25
2023-12-31-$1.40M
10-K · filed 2026-02-25
2022-12-31-$11.10M
10-K · filed 2025-02-12
2021-12-31-$2.50M
10-K · filed 2024-02-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76